Planning for 2027 Like It's 2026

The market is changing faster than the planning cycle. Allocating next year's budget the way you allocated this year's is planning to lose the same patients again.

Right now, across pharma, 2027 plans are being built. Budgets allocated, headcount mapped, priorities set function by function. It's the annual rhythm, and most of it will follow the shape it followed last year: give each function its slice, ask each to optimize its own leg, roll it up into a plan.

There's a problem with running that same play into 2027. The market it was designed for is already gone.

The cycle is slower than the market

Annual planning assumes a certain stability — that the landscape you're planning for looks roughly like the one you planned for last time. That assumption is getting harder to defend. Biosimilar and generic entry is compressing timelines. Launch windows are tightening. The tools available shift every few months. Buyers, payers, and patients are all moving faster than a twelve-month cycle can absorb.

When the market changes faster than the planning cycle, planning by repetition quietly stops working. You're allocating 2027 resources against a 2026 picture of where value comes from — and in a fast-moving market, last year's picture is already out of date by the time the budget locks.

The functional plan is especially vulnerable to this, because it optimizes the parts that were already visible. It makes each function a little more efficient at what it already did. What it doesn't do is ask whether the thing that actually differentiates value has changed — and in a faster market, it usually has.

Efficiency in the 10% isn't differentiation anymore

Here's the part worth sitting with during planning season. Most of what a functional plan optimizes lives in the 10% of the patient journey that's already visible and owned — enrollment, activation, the first fill, each function's measurable slice. Planning tends to pour next year's budget into making those pieces incrementally better.

But in a market where everyone is optimizing the same visible 10%, doing it slightly more efficiently isn't a differentiator. It's table stakes. Your competitors are running the same play, funding the same functions, tightening the same steps. A 2027 plan that just does the 10% a little better produces a company that looks a lot like every other company — and loses patients in the same places.

What actually differentiates value is the 90% — the long stretch between visits where persistence is won or lost, in the handoffs no single function owns. It's the part competitors optimizing their own functions won't build, precisely because it doesn't belong to any one function's plan. In a fast-changing market, the durable advantage isn't a more efficient 10%. It's the persistence infrastructure in the 90% that almost no one is planning for.

Budget season is the window — and it closes

The reason this matters now, specifically, is that planning season is the one moment the 90% can actually get funded on purpose.

The 90% goes unbuilt most years not because anyone decides against it, but because it never makes it into the plan — it has no functional owner to champion it, so when budgets are allocated function by function, it falls between the lines. Once the 2027 plan locks, that's set for another year. The gap that had no owner in planning will have no budget in execution, and the patients will fall through it on schedule.

Which means the differentiated 2027 plan isn't built by planning harder within functions. It's built by doing one thing the normal cycle skips: identifying, before the budget locks, where persistence is actually breaking across the functions — and funding that deliberately, as its own priority, rather than hoping it gets covered by the sum of the functional slices.

That prioritization — knowing which cross-functional gaps matter most before you allocate against them — is what our patent-pending diagnostic, the Gap Finder, was built to produce: a ranked, measurable view of where the 90% is leaking, so 2027 budget can be pointed at what differentiates value rather than at what was easy to plan for. The tool is downstream of the decision. The decision is refusing to plan the 90% by accident for one more year.

The question worth asking before the plan locks

As the 2027 numbers come together, one question is worth putting on the table before they're final:

Does this plan fund where patients actually fall through — or does it fund each function doing what it already did, and assume the gaps between them will take care of themselves?

If it's the latter, the plan is optimized for a market that's already changing out from under it. It will make each function more efficient and leave the differentiator unbuilt for another year.

The market is moving faster than the cycle. Planning for 2027 like it's 2026 doesn't just repeat last year — in a faster market, it falls further behind.

Linked Patient Learning helps pharma teams see where patient persistence is breaking across functions — so 2027 planning can fund what differentiates value, not just what was easy to plan for.